Why are you expecting big advances in the treatment of central nervous system diseases over the next few years?
The greatest biotech treatment advances of the next five or ten years are expected to occur in neuroscience, with novel treatments under development in SMA, Huntington’s, Autism, ALS, DMD, Parkinson’s and Alzheimer’s.
Recent reorganization of the FDA includes establishment of an Office of Neuroscience, driven by FDA’s focus on the great unmet need in this area, and an upcoming wave of new high-technology drug candidate reviews. Given the paucity of treatment options for diseases such as Alzheimer’s, any safe and effective therapy that makes it to market would be widely adopted.
What we’re watching:
- Biogen’s aducanumab data
- Roche’s gantenerumab and anti-tau trials
- FDA regulatory flexibility
- FDA Office of Neuroscience
People in us suffering from Alzheimer’s
Meetings of FDA’s peripheral central nervous system drugs advisory committee in 2019
Estimated US TAM for Aducanumab if approved
Alzheimer’s drugs that have failed in previous clinical trials